Who Paid My Doc
Ontak
Drug Oncology
NDC 62856-603-01
General payments
$116,290
Research payments
$4,765,397
Through program year 2024, $116,290 in general payments and $4,765,397 in research payments were reported against Ontak (Oncology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
10 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $1,690 | 1 |
| 2023 | General | $6,150 | 1 |
| 2023 | Research | $74,825 | 34 |
| 2022 | General | $23,660 | 4 |
| 2022 | Research | $1,093,620 | 418 |
| 2021 | General | $81,680 | 37 |
| 2021 | Research | $580,902 | 355 |
| 2020 | General | $4,800 | 5 |
| 2020 | Research | $1,262,455 | 901 |
| 2019 | Research | $1,751,905 | 1,121 |
Breakdown
Each share is of general payments naming this product in 2023.
Each share is of general payments naming this product to practitioners with a specialty in 2023. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2023 where a state was reported.
Records
47 general · 2,830 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.